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Abstract
The deleterious impact of diabetes on the retina is a leading cause of vision
loss. Ultimately, the hypoxic retinopathy caused by diabetes results in irre-
versible damage to vascular, neuronal, and glial cells. Less understood is how
retinal physiology is altered early in the course of diabetes. We recently found
that the electrotonic architecture of the retinovasculature becomes fundamen-
tally altered soon after the onset of this disorder. Namely, the spread of volt-
age through the vascular endothelium is markedly inhibited. The goal of this
study was to elucidate how diabetes inhibits electrotonic transmission. We
hypothesized that vascular endothelial growth factor (VEGF) may play a role
since its upregulation in hypoxic retinopathy is associated with sight-impair-
ing complications. In this study, we quantified voltage transmission between
pairs of perforated-patch pipettes sealed onto abluminal cells located on reti-
nal microvascular complexes freshly isolated from diabetic and nondiabetic
rats. We report that exposure of diabetic retinal microvessels to an anti-VEGF
antibody or to a small-molecule inhibitor of atypical PKCs (aPKC) near-fully
restored the efficacy of electrotonic transmission. Furthermore, exposure of
nondiabetic microvessels to VEGF mimicked, via a mechanism sensitive to the
aPKC inhibitor, the diabetes-induced inhibition of transmission. Thus, activa-
tion of the diabetes/VEGF/aPKC pathway switches the retinovasculature from
a highly interactive operational unit to a functionally balkanized complex. By
delimiting the dissemination of voltage-changing vasomotor inputs, this orga-
nizational fragmentation is likely to compromise effective regulation of retinal
perfusion. Future pharmacological targeting of the diabetes/VEGF/aPKC path-
way may serve to impede progression of vascular dysfunction to irreversible
diabetic retinopathy.
Introduction
The constellation of injurious effects of diabetes on the
vascular, glial, and neuronal components of the retina
ranks as a leading cause of visual impairment. One of the
early targets of diabetes-induced dysfunction is the reti-
na’s circulatory system whose ability to adjust blood flow
to meet metabolic demand rapidly becomes impaired
(Kohner et al. 1995; Ciulla et al. 2002; Clermont and Bur-
sell 2007). In turn, vascular dysregulation impearls the
functioning of retinal neurons and glia.
It appears likely that the particular vulnerability of reti-
nal vasculature to diabetes is a consequence of the highly
specialized adaptations required to meet the unique chal-
lenge of distributing nutrients and oxygen within a tissue
whose transparency is essential for light perception (Puro
2012). A distinctive adaptation is the low density of
microvessels within the retina (Funk 1997). Yet, even
though this sparseness minimizes vascular interference
with photons passing to the photoreceptors, the paucity
of vessels leaves little functional reserve for maintaining
adequate perfusion to meet the stringent metabolic
requirements of the retinal neurons. On the other hand, a
reserve capacity to adjust blood flow in response to sys-
temic conditions is not needed because of the unique
independence of the retinal vasculature from extrinsic
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control. Namely, its lack of autonomic innervation (Ye
et al. 1990) and the tight blood-retina barrier preclude
CNS oversight and exposure of contractile abluminal cells
to circulating vasoactive molecules. With the absence of
extrinsic input, the retina autonomously regulates its
blood flow. Furthermore, effective and efficient autoregu-
lation is facilitated by the retinovasculature’s highly inter-
active electrotonic architecture (Wu et al. 2006; Zhang
et al. 2011), which provides the functional infrastructure
needed to spatially integrate voltage-changing vasomotor
signals generated at sites throughout the vascular network
(Wu et al. 2001; Yamanishi et al. 2006; Puro 2007). How-
ever, early in the course of diabetes, electrotonic transmis-
sion within retinal microvessels becomes markedly
impaired (Nakaizumi et al. 2012), and the ability of the
retina to autoregulate blood flow is lost (Kohner et al.
1995; Ciulla et al. 2002; Clermont and Bursell 2007).
The present study builds upon results of earlier electro-
physiological analyses demonstrating that diabetes results
in the inhibition of gap junction-dependent communica-
tion in the retinal microvasculature (Oku et al. 2001;
Nakaizumi et al. 2012; Tien et al. 2016; Roy et al. 2017).
More specifically, dual perforated-patch recordings from
microvascular complexes freshly isolated from the retinas
of rats with streptozotocin-induced diabetes revealed a
marked attenuation in the efficacy at which voltage
spreads axially through microvessels (Nakaizumi et al.
2012). This inhibition of voltage transmission was
detected ~5 weeks after the onset of hyperglycemia, which
is well before widespread cell death detected in the dia-
betic rat retina (Mizutani et al. 1996; Gardiner et al.
2007; Barber et al. 2011). The aim of the current study
was to elucidate the mechanism by which diabetes inhi-
bits axial transmission in the retinovasculature.
Here, we report that endogenous vascular endothelial
growth factor (VEGF) near-totally accounts for the inhi-
bition of axial transmission observed in diabetic retinal
microvessels. In addition, indicative of a key role for
atypical PKC isoforms (aPKC), we found that the inhibi-
tory effect of diabetes and VEGF on axial transmission is
highly sensitive to a specific, noncompetitive, small-mole-
cule inhibitor of aPKC. Taken together, our new observa-
tions support for a working model in which activation of
the diabetes/VEGF/aPKC pathway markedly delimits the
spatial dissemination of voltage-changing inputs within
the retinovascular network.
Materials and Methods
Animal use conformed to the American Physiological
Society’s Guiding Principles in the Care and Use of Verte-
brate Animals in Research and also received approval
from the Institutional Animal Care and Use Committee
of the University of Michigan. Male Long-Evans rats were
obtained from Charles River (Cambridge, MA, USA). At
all times, animals were kept on a 12-h alternating light/
dark cycle and received food and water ad libitum.
Model of diabetes
Diabetes was induced by one or two intraperitoneal injec-
tions of streptozotocin (150 mg kg1 diluted in 0.8 mL
citrate buffer) into 5-week-old rats that had fasted for
5 h. The diabetic rats used in this study were hyper-
glycemic for 10.3  1.0 weeks (n = 13) and had a blood
glucose level of 420  39 mg dL1 immediately retino-
vessel isolation. Of note, 10 weeks of hyperglycemia are
well before vascular cell death is detected in the diabetic
rat retina (Mizutani et al. 1996). At the time of sacrifice,
the ages of diabetic and nondiabetic rats were not signifi-
cantly different.
Microvessel isolation
Using a previously described tissue print procedure (Puro
2012; Puro et al. 2016), we isolated large complexes of
microvessels from the retinas of adult rats. In brief,
immediately after a rising concentration of carbon
dioxide-induced death, the retinas were removed and
placed in solution A, which consisted of 140 mmol/L
NaCl, 3 mmol/L KCl, 1.8 mmol/L CaCl2, 0.8 mmol/L
MgCl2, 10 mmol/L Na-Hepes, 15 mmol/L mannitol, and
5 mmol/L glucose at pH 7.4 with osmolarity adjusted to
310 mosmol L1, as measured by a vapor pressure
osmometer (Wescor, Inc., Logan, UT, USA). After
removal of adherent vitreous, each retina was cut into
quadrants and incubated for 22–26 min at 30°C in
2.5 mL Earle’s balanced salt solution supplemented with
0.5 mmol/L EDTA, 6 U papain (Worthington Biochemi-
cals, Freehold, NJ, USA) and 2 mmol/L cysteine; the pH
was adjusted to approximately 7.4 by bubbling 5% carbon
dioxide. After this incubation, the retinal pieces were
transferred to a 60 mm Petri dish containing 5 mL of
solution A, and one by one, each retinal quadrant was
positioned with its vitreal surface up in a glass-bottomed
chamber containing 1 mL of solution A. Subsequently,
each retinal quadrant was gently sandwiched between the
bottom of the chamber and a 15 mm diameter glass cov-
erslip (Warner Instrument Corp., Hamden, CT, USA).
After ~30 sec, the coverslip was carefully removed; it con-
tained adherent complexes of retinal microvessels, as
shown in photomicrographs in Figure 1A and previous
publications (Matsushita et al. 2010; Puro 2012). Of note,
the correlative anatomical organization of the rat retinal
vasculature in vivo and of the retinal microvascular com-
plexes freshly isolated from the rat is available (Puro
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2012). A vessel-containing coverslip was positioned in a
recording chamber (volume = 0.5 mL) that could be per-
fused at 2 mL/min with solutions from a gravity-fed sys-
tem using multiple reservoirs.
Electrophysiology
Experiments were conducted at room temperature within
5 h after isolation of a microvascular complex. Similar to
previous studies (Wu et al. 2006; Zhang et al. 2011;
Nakaizumi et al. 2012), dual perforated-patch recordings
were used to quantify the efficacy of electrotonic trans-
mission. With earlier analysis demonstrating that diabetes
similarly affects electrotonic transmission at all levels of
the retinal vascular network (Nakaizumi et al. 2012), this
study focused on the secondary retinal arterioles. Of
practical importance, the plump “doughnut-shaped”
myocytes encircling the secondary arterioles (Puro 2012)
provide relatively easy targets for obtaining stable patch
pipette/abluminal seals. Thus, by focusing on these
microvessels, it was feasible to obtain sufficient numbers
of high-quality electrophysiological measurements to yield
robust, reliable data. Hence, both pairs of recording pip-
ettes were sealed onto a secondary arteriole. Furthermore,
the outer diameter of the sampled secondary arteriole
was similar at both recording sites. Although some sam-
pled secondary arterioles possessed branching vessels
(e.g., Fig. 1A), both recording pipettes were on the tar-
geted secondary arteriole; hence, secondary-to-tertiary
arteriolar transmission was not assessed. Notable is that
branch points within secondary retinal arterioles do not
significantly alter the efficacy of electrotonic transmission
(Zhang et al. 2011).
Each recording pipette, which had a resistance of 5–
10 MΩ and contained a solution consisting of 50 mmol/L
KCl, 65 mmol/L K2SO4, 6 mmol/L MgCl2, 10 mmol/L K-
Hepes, 60 lgmL1 amphotericin B and 60 lgmL1 nys-
tatin at pH 7.35 and osmolarity at 280 mosmolL1, was
mounted in the holder of a patch-clamp amplifier (Axo-
patch 200B, MDS Analytical Technologies, Union City,
CA). A piezoelectric-based micromanipulator (Exfo,
Thorlabs, Newton, NJ) facilitated the positioning of the
tip of a recording pipette onto to an abluminal cell while
the microvasculature complex was viewed at 9400 via an
inverted microscope equipped with phase-contrast optics.
As suction was applied to the back end of the pipette, a
≥10 GΩ seal formed. Subsequently, a second recording
pipette was sealed onto the same microvessel (Fig. 1A).
Interpipette distance was measured from a photomicro-
graph of the sampled microvascular complex containing
the two recording pipettes (Fig. 1A). Data are from
recordings in which the access resistances were ≤35 MΩ.
Voltages were filtered with a four-pole Bessel filter, sam-
pled digitally using a DigiData 1440A acquisition system
(MDS Analytical Technologies) and stored by a computer
equipped with pClamp (version 10, MDS Analytical Tech-
nologies), which along with other software (Origin 2017,
OriginLab, Northampton, MA, USA), aided with data
analysis and graphics display.
For each pair of dual recordings, a 750-msec hyperpo-
larizing current step was injected at 3-sec intervals via
one of the two recording pipettes as the membrane
potentials of the current-injected (stimulator) abluminal
cell and the other monitored mural cell (responder) were
recorded (Fig. 1B). The averaging of voltage traces
obtained during 10–30 cycles of current injection facili-
tated quantification of the voltage changes at the stimu-
lated (DVstimulator) and the nonstimulated (DVresponder)
sites. Of note, in the retinovasculature there is no signifi-
cant difference in DVresponder/DVstimulator ratios generated
A B
Figure 1. Dual perforated-patch recordings from a retinal microvascular complex freshly isolated from a diabetic rat. (A) photomicrograph
showing a pair of recording pipettes (arrows) at an interpipette distance of 973 lm. (B) left panel, voltage trace during administration via one
of the pipettes (stimulator) of a 750-msec duration 25-pA hyperpolarizing current. Right panel, voltage trace recorded by the other pipette
(responder). To aid visualization, the voltage change at the responding site is displayed at a 5-fold larger gain.
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by depolarization or hyperpolarization (Wu et al. 2006;
Zhang et al. 2011). Conduction through the bathing solu-
tion, rather than through the microvessel, did not con-
tribute to the observed DVresponder since pipette-to-pipette
transmission was not detected after one of the two
recording seals was spontaneously lost or when one of the
pipettes was positioned close to, but not sealed onto the
microvessel.
Analysis of DVresponder/DVstimulator
measurements
Calculations of the efficacies of axial and radial transmis-
sion were based on our previous analysis (Zhang et al.
2011) showing that a voltage generated by injecting cur-
rent into an abluminal cell is initially transmitted radially
to the underlying endothelium, then is transmitted axially
through endothelium and finally is transmitted radially to
the distantly monitored abluminal cell (responder). Nota-
ble is that direct electrotonic communication between
adjacent abluminal cells is minimal in retinal microvessels
(Zhang et al. 2011). Our previous analysis also showed
that voltage decay during axial transmission is described
by a first-order exponential process dependent upon
interpipette distance (Zhang et al. 2011). In the present
study, we measured DVresponder/DVstimulator ratios at inter-
pipette distances of ≤250 lm (“short” group) and 650–
1150 lm (“long” group). By focusing recording efforts on
these two groups, it was feasible to measure a sufficient
number of DVresponder/DVstimulator ratios to establish reli-
able values for the mean DVresponder/DVstimulator ratios
used in the formula: A(bc)/100 lm = d/e where “A” is the
efficacy per 100 lm, “b” is the mean interpipette distance
for the “long” interpipette distance group, “c” is the
mean interpipette distance for the short distance group,
“d” is the mean DVresponder/DVstimulator ratio for the short
interpipette distance group, and “e” is the mean
DVresponder/DVstimulator ratio for the long distance group.
In turn, the percent voltage loss per 100 lm of axial
transmission was [(1  A)100]. As previously detailed
(Zhang et al. 2011; Nakaizumi et al. 2012), DVresponder/
DVstimulator ratios were also used to calculate the efficacy
of radial transmission. In brief, with the aid of commer-
cially available software (OriginLab), the extrapolated
DVresponder/DVstimulator ratio at the y-intercept was com-
puted. With the hypothetical interpipette distance being
0 lm at the y-intercept, the extrapolated DVresponder/
DVstimulator ratio is not affected by axial transmission, but
is determined by radial transmissions from stimulated
abluminal cell to endothelium and from endothelium to
the responder. Hence, the square root of the extrapolated
DVresponder/DVstimulator ratio at 0 lm is the efficacy of a
radial transmission. From this efficacy, it is
straightforward to calculate the percent of voltage lost
during a radial transmission.
Chemicals
The specific inhibitor of atypical PKC, propan-2-yl 2-
amino-4-(3,4-dimethoxyphenyl)thiophene-3-carboxylate
(Titchenell et al. 2013), was a gift from David Antonetti.
Other chemicals were from MilliporeSigma (St. Louis,
MO) including recombinant rat vascular endothelial
growth factor 164 (MilliporeSigma catalog number
V3638) and an anti-VEGF antibody developed in goat
using a purified 164 amino acid residue variant of recom-
binant mouse VEGF (MilliporeSigma V1253; RRID:
AB_261846).
Statistics
Data are given as mean  SE. Probability was evaluated
by Student’s two-tailed t-test, with equal or unequal vari-
ance, as appropriate. For comparison of two groups,
P > 0.05 indicated failure to detect a significant differ-
ence. The Bonferroni correction was used to adjust the P-
value for significance when >2 groups were compared
(Figs. 4 and 6).
Results
The aim of this study was to elucidate how diabetes alters
the electrotonic architecture of the retinal microvascula-
ture. Previously, simultaneous dual perforated-patch
recordings revealed that the axial spread of voltage
through the endothelium is markedly inhibited in diabetic
retinal microvessels (Nakaizumi et al. 2012). As a frame-
work for the present study, we hypothesized that vascular
endothelial growth factor (VEGF) may play a key role in
mediating this diabetes-induced inhibition of axial trans-
mission. VEGF was of interest since its upregulation is
known to play a role in diabetic retinopathy (Antonetti
et al. 2012; Jiang et al. 2015; Kida et al. 2017) and gap
junction-dependent intercellular communication in vari-
ous nonretinal vascular cells can be inhibited by VEGF
(Suarez and Ballmer-Hofer 2001; Thuringer 2004; Nim-
lamool et al. 2015). To assess the putative role of VEGF,
microvessels freshly isolated from diabetic retinas were
preexposed for >1 h to an anti-VEGF antibody (3 lg/
mL). Subsequently, DVresponder/DVstimulator ratios were
measured via dual recording pipettes (Fig. 2A). In other
experiments, dual recordings were also obtained from dia-
betic microvessels in the absence of the antibody
(Fig. 2A). Analysis of the DVresponder/DVstimulator ratios
revealed that anti-VEGF treatment attenuated by 8-fold
(P = 0.0002) the rate of voltage decay during axial
2019 | Vol. 7 | Iss. 9 | e14095
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transmission (Fig. 2B). This robust effect indicates that
endogenous VEGF plays a key role in mediating the dia-
betes-induced inhibition of axial transmission.
In complementary experiments, we tested the effect of
exogenous VEGF on axial transmission in microvessels
from nondiabetic retinas. Specifically, prior to measuring
DVresponder/DVstimulator ratios, nondiabetic retinal micro-
vessels were preincubated for >1 h in the absence or pres-
ence of 100 ng/mL VEGF (Fig. 3A), which is the reported
concentration at which there is near-maximal binding to
VEGF receptors (Matsumoto and Claesson-Welsh 2001;
Krilleke et al. 2007). Analysis of the measured DVresponder/
DVstimulator ratios showed that treatment with VEGF
markedly increased (P = 0.0029) the rate of voltage
decay during axial transmission (Fig. 3B). Of note, this
series of experiments performed under normoglycemic
conditions shows that the ability of VEGF to increase the
voltage decay rate does not require an elevated concentra-
tion of glucose. In addition, this effect was not associated
with a change in the recorded membrane potential, which
was 44  1 mV in the absence (n = 28) and presence
of VEGF (n = 47). Also of note, the voltage decay rates
during axial transmission in diabetic microvessels
(Fig. 2B) and in VEGF-treated nondiabetic microvessels
(Fig. 3B) were not significantly different. Thus, exposure
of nondiabetic retinal microvessels to exogenous VEGF
mimicked the diabetes-induced inhibition of axial
transmission.
To further assess the ability of VEGF to mimic the
effect of diabetes on the electrotonic architecture, we
asked whether VEGF, like diabetes (Matsushita et al.
2010), fails to significantly alter radial transmission.
Indicative that this is in fact the case, analysis of
DVresponder/DVstimulator ratios measured in nondiabetic
microvessels (Fig. 3A) showed that voltage decay during
radial transmission was not significantly altered by
VEGF. Namely, in nondiabetic microvessels, voltage loss
during radial transmission in the absence of VEGF was
50  2% and in the presence of VEGF, 52  2%. Fur-
thermore, anti-VEGF treatment of diabetic microvessels
did not significantly alter voltage decay during radial
transmission; decay was 49  2% in the absence of this
antibody and 53  6% in its presence. Based on these
observations, we concluded that neither diabetes nor
VEGF impairs radial transmission in retinal microvessels.
Rather, as observed in diabetic retinal vessels, VEGF
selectively inhibits axial transmission.
To further elucidate the mechanism by which diabetes
inhibits axial transmission in retinal microvessels, we pos-
tulated that the protein kinase C (PKC) family of
enzymes plays a role. PKC was of interest since VEGF can
activate PKC (Das Evcimen and King 2007; Titchenell
et al. 2012) and in various cell types, PKC activation inhi-
bits gap junction function (Suarez and Ballmer-Hofer
2001; Thuringer 2004; Nimlamool et al. 2015). To begin
to assess the putative role of PKC, we measured
Figure 2. Effect of an anti-VEGF antibody on electrotonic transmission in diabetic retinal microvessels. (A) DVresponder/DVstimulator ratios obtained
at relatively short (left panel) and long (right panel) interpipette distances in the absence or presence for >2.5 h of 3 lg/mL anti-VEGF. Data
points in the absence of the antibody include four in the short interpipette distance group and three in the long group from Nakaizumi et al.
(2012). (B) mean DVresponder/DVstimulator ratios plotted at the mean interpipette distances. Voltage decay rates calculated as described in the
Materials and Methods are shown. *P = 0.0002.
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DVresponder/DVstimulator ratios in diabetic retinal microves-
sels exposed for >1 h to the broad-spectrum PKC inhibi-
tor, chelerythrine (1 lmol/L; Fig. 4A). Analysis of
DVresponder/DVstimulator ratios showed that chelerythrine
significantly lessened (P = 0.0022) the diabetes-induced
inhibition of axial transmission (Fig. 4B).
With emerging evidence that atypical PKC (aPKC) iso-
forms may be involved in diabetic vascular complications
Figure 3. Effect of VEGF on electrotonic transmission in nondiabetic retinal microvessels. (A) DVresponder/DVstimulator ratios at short (left panel)
and long (right panel) interpipette distances in the absence or presence for > 1 h of 100 ng/mL VEGF. Data points in the absence of VEGF
include five in the short group and two in the long group from Nakaizumi et al. (2012). (B) mean DVresponder/DVstimulator ratios plotted at the
mean interpipette distances. Voltage decay rates are shown. *P = 0.0029.
Figure 4. Effect of PKC inhibitors on electrotonic transmission in diabetic retinal microvessels. (A) DVresponder/DVstimulator ratios at short (left
panel) and long (right panel) interpipette distances in the absence (data from Fig. 2A) or presence for > 1 h of either the nonspecific PKC
inhibitor chelerythrine (1 lmol/L) or 100 nmol/L of a specific aPKC inhibitor. (B) means of the data in A plotted at the mean interpipette
distances. Voltage decay rates per 100 lm are show. *P ≤ 0.0022.
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(Wellner et al. 1999; Titchenell et al. 2012; Lin et al.
2018), we also tested the effect of the specific, potent,
noncompetitive, small-molecule inhibitor of aPKC
inhibitor, propan-2-yl 2-amino-4-(3,4-dimethoxyphenyl)
thiophene-3-carboxylate (100 nmol/L). Dual recording
experiments showed that exposure of diabetic retinal
microvessels to this aPKC inhibitor near-fully reversed
(P = 0.0001) the inhibition of axial transmission (Fig. 4).
Also indicative of the importance of aPKC, additional
recordings demonstrated that exposure of nondiabetic
microvessels to the small-molecule aPKC inhibitor largely
prevented the VEGF-induced inhibition of axial transmis-
sion (Fig. 5).
Taken together, the results of the dual recording exper-
iments summarized in Figure 6 support a pathophysio-
logical scenario in which endogenous VEGF and the
activation of aPKC mediate the diabetes-induced inhibi-
tion of axial transmission in the retinovasculature.
Discussion
This analysis of the electrotonic transmission in retinal
microvessels provides evidence that endogenous VEGF,
via an aPKC-dependent mechanism, mediates the dia-
betes-induced inhibition of axial transmission. Using dual
perforated-patch recordings from microvessels freshly iso-
lated from the retinas of rats made diabetic by streptozo-
tocin, we demonstrated that exposure to an anti-VEGF
antibody or to a small-molecule inhibitor of aPKC
restored the efficacy of axial transmission to the level
observed in nondiabetic retinal microvessels. Conversely,
dual recordings also established that by a mechanism
Figure 5. Effect of an inhibitor of aPKC on the VEGF-induced boost in voltage decay in nondiabetic microvessels. (A) DVresponder/DVstimulator
ratios measured at short (left panel) and long (right panel) interpipette distances in nondiabetic microvessels exposed for >2.5 h to 100 ng/mL
VEGF in the absence (data from Fig. 3A) or presence of the specific aPKC inhibitor (100 nmol/L) for > 1 h. (B) means of the data in A plotted
at the average interpipette distances. Rates of voltage decay per 100 lm are shown. *P = 0.0117.
Figure 6. Voltage decay rates during axial transmission in diabetic
and nondiabetic retinal microvessels under various experimental
conditions. The diabetic group (top row), as well as the
nondiabetic/VEGF group (sixth row), had significantly more rapid
voltage decay rates than those measured in the other experimental
groups.
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sensitive to the aPKC inhibitor, exposure of nondiabetic
retinal microvessels to exogenous VEGF mimicked the
inhibitory effect of diabetes on axial transmission. This
analysis revealed that activation of the diabetes/VEGF/
aPKC pathway markedly delimits the spatial dissemina-
tion of focally induced voltage changes. For example, cal-
culations using the measured DVresponder/DVstimulator
ratios indicate that activation of this pathway boosts
voltage loss from 8% to 50% during a 400-lm axial
transmission and from 50% to 99.5% during a 3200-lm
transmission. We posit that this functional fragmentation
impairs the ability of the retinovasculature to effectively
integrate the many voltage-changing vasomotor signals
(Li and Puro 2001; Wu et al. 2001; Yamanishi et al. 2006;
Puro 2007) generated at sites through the vascular
network.
The new observation that VEGF alters the electrotonic
architecture of the retinal vasculature raises the question
as to whether this molecule also inhibits intercellular
communication in other vasculatures. Indicative of this,
exposure of nonretinal endothelial cells to VEGF can inhi-
bit cell-to-cell communication via gap junctions (Suarez
and Ballmer-Hofer 2001; Thuringer 2004; Nimlamool
et al. 2015), whose closure is known to modulate angio-
genesis (Fang et al. 2011, 2012; Gartner et al. 2012; Oka-
moto et al. 2014). In addition to altering gap junction
function, retinal and nonretinal vasculatures share other
responses to VEGF. For example, a common response is
increased leakage of serum-derived angiogenic molecules
(Ferrara 1999; Bao et al. 2009; Titchenell et al. 2012).
Also, VEGF directly stimulates the growth of neovessels
in numerous tissues including the retina (Ferrara 1999;
Melincovici et al. 2018). Yet, despite these similarities,
VEGF elicits a beneficial adaptive response to hypoxia
only in nonretinal tissues (Dor et al. 2002). In the
hypoxic retinopathy of diabetes, sickle cell disease or pre-
mature birth, endogenous VEGF stimulates the growth of
grossly aberrant neovessels that fails to enhance effective
retinal perfusion, are prone to vision-impairing hemor-
rhages and, by generating tractional forces, can cause
blinding retinal detachments. Furthermore, although a
VEGF-induced leakage of angiogenic molecules from non-
retinal vessels facilitates a well-adapted neovascular
response (Bao et al. 2009), the VEGF-triggered break-
down of the blood-retinal barrier results in edematous
swelling that can impair sight by disrupting the retina’s
highly specialized morphological and functional organiza-
tion (Antonetti et al. 2012). Additionally, as noted, the
diabetes/VEGF/aPKC-induced restriction in the electro-
tonic dissemination of voltage-changing vasomotor inputs
is likely to compromise the unique ability of the retina to
autoregulate its blood flow. Thus, there is a stark dichot-
omy in the adaptive effectiveness of VEGF at nonretinal
and retinal sites. We postulate that the adaptive role of
VEGF in nonretinal tissues has been honed throughout
much of mammalian evolution to effectively ameliorate
hypoxia. In contrast, with life expectancy having increased
only recently for diabetics and others prone to hypoxic
retinopathy, there has been insufficient time for evolu-
tionary pressure to tailor the responses of the retina to
VEGF so that hypoxia is ameliorated while optimal light
detection is maintained.
This analysis of electrotonic transmission in the retino-
vasculature was based on analysis of freshly isolated
microvascular complexes. With this experimental prepara-
tion, it is quite feasible to obtain dual perforated-patch
recordings at specific microvascular locations. Further-
more, use of isolated retinal microvessels allowed assess-
ment of the effects of VEGF and inhibitors of PKC in the
absence of confounding actions mediated via nonvascular
cells. On the other hand, effects on voltage transmission
of the numerous vasomotor signals generated within the
retina (Puro 2007) were not assessed. Also, because
the isolated microvessels were not internally perfused, the
effect of intraluminal pressure on electrotonic transmis-
sion was not evaluated. Additionally, even though the
conduction of electric signals has been intensively studied
in nonretinal vasculatures (Figueroa and Duling 2009;
Behringer and Segal 2012), the effect of diabetes on volt-
age transmission in these vascular beds has yet to be
explored. Also, future studies of interest include measure-
ment of abluminal VEGF levels on diabetic microvessels,
identification of the connexins affected by the diabetes/
VEGF/aPKC pathway and determination of this pathway’s
impact on the autoregulation of retinal blood flow. It is
clear that pathophysiological mechanisms characterized in
isolated vascular complexes will require in vivo verifica-
tion, although technical advances are required to allow
quantification of electrotonic transmission within the vas-
culature of the in vivo retina.
The key conclusion of this study is that the mechanism
by which diabetes inhibits axial transmission in the retina
microvasculature is near-totally due to the actions of
VEGF and aPKC. Further, the results show for the first
time that exposure to anti-VEGF antibodies, which are
now commonly used in the treatment of complications of
diabetic retinopathy (Apte et al. 2019), increases in the
efficacy of axial transmission in diabetic retinovessels.
This raises the possibility that this previously unappreci-
ated action of anti-VEGF may play a role in its therapeu-
tic impact.
Our experiments using nondiabetic microvessels under
normoglycemic conditions demonstrate that an elevated
concentration of glucose is not required for the VEGF-
induced inhibition of transmission. This finding supports
the possibility that the VEGF/aPKC pathway may also
2019 | Vol. 7 | Iss. 9 | e14095
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impair electrotonic transmission in nondiabetic condi-
tions, such as sickle cell retinopathy, in which VEGF pro-
duction is induced by retinal hypoxia. On the other hand,
in contrast to the pathophysiological importance of VEGF
in the adult retina, the minimal amount of this growth
factor in the mature retina (Penn et al. 2008; Shimada
et al. 2009) suggests a minor physiological role.
In conclusion, results from our dual perforated-patch
recordings indicate that early in the course of diabetes, a
mechanism dependent on VEGF and aPKC inhibits axial
transmission in retinal microvessels. In this way, the elec-
trotonic architecture of the retinovasculature is switched
from a highly interactive global system to a functionally
balkanized complex. We proposed that the organizational
disruption induced by the diabetes/VEGF/aPKC pathway
plays a previously unappreciated role in the blood flow
dysregulation that occurs early in the course of diabetes.
In the future, pharmacological manipulation of the dia-
betes/VEGF/aPKC pathway may provide a new strategy
for preventing perturbations in retinovascular function
from progressing to irreversible sight-impairing diabetic
retinopathy.
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